Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIME-Lung: Up-front Radiotherapy With Standard-of-care Systemic Therapy in Advanced Lung Cancer
NCT07135882Phase 3Recruiting
- Sponsor
- Trans-Tasman Radiation Oncology Group
- Start
- Oct 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 3, randomised trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Trans-Tasman Radiation Oncology Group. Primary endpoint: Overall Survival at 5 years. Started Oct 2026; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07135882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07135882.